MedPath

Causal Inference Research of Resistant Hypertension Treatment With Chinese Approach in a Cohort Study

Early Phase 1
Completed
Conditions
Hypertension, Resistant to Conventional Therapy
Primary Hypertension
Interventions
Drug: Herbs
Drug: Antihypertensive drugs
Registration Number
NCT01904695
Lead Sponsor
China Academy of Chinese Medical Sciences
Brief Summary

The research of clinical effectiveness assessment is to explore the causal relationship between treatment and outcome.Accordingly, based on the effectiveness of tan-yu treatment, the research takes the Resistant Hypertension (RH) as example to study the causal inference methods under real world.

Detailed Description

Background: Syndrome differentiation is one of the substantial characteristics in Traditional Chinese Medicine (TCM) but is still lack of scientific evidence.The inference methods of causal relationship between treatment and clinial effect under real-word study may help.

Objectives: This study aims to assess the efficacy of Phlegm and Stasis Syndrome differentiation method in treating resistant hypertension and explore causal inference in the real-world study.

Research design and methods: It is a multi-center,prospective,two-arm,cohort study including 200 patients with resistant hypertension (doctors' diagnosis based on the American Heart Association criteria 2008).Essential hypertension subjects,aged 18-70 years,blood pressure \>140/90mmHg even used to be on 3 or more medications for a month and diagnosed as Phlegm and Stasis Syndrome will be included.Thiazide diuretics and/or two more antihypertensive agents for 8 weeks, Chinese herbs (for synchronic treating phlegm and blood stasis) and nonpharmacological recommendations were initiated in the observational group and the control group received the same interventions without Chinese herbs.

Outcome measures: The primary outcomes will be Systolic (SBP) and Diastolic (DBP) blood pressure reductions and changes in symptoms and signs.Cardiac event and death incident will be the secondary outcomes.Possible side effects and adverse reactions arising from the treatment like diarrhea will be recorded.

Discussion: This is a rigorous methodology pilot study and 200 patients are enough to calculate sample size in later formal trial.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
192
Inclusion Criteria
  • Essential hypertension subjects, aged 18-70 years, blood pressure > 140/90 mm Hg even used to be on 3 or more medications for a month and diagnosed as Phlegm and Stasis Syndrome will be included.
Exclusion Criteria
  • Patients will be excluded for the following conditions: with secondary resistant hypertension because of other disease like renal disease or pheochromocytoma; included in other clinical trial in one month; pregnant or breast-feed or preparing for pregnancy female; combined with disease like stroke, coronary atherosclerotic heart disease, diabetes, chronic renal failure or mental disease.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Antihypertensive drugs & HerbsHerbsThiazide diuretics and ACE inhibitor and β-blocker \& Herbs for 8 weeks
Antihypertensive drugs & HerbsAntihypertensive drugsThiazide diuretics and ACE inhibitor and β-blocker \& Herbs for 8 weeks
Antihypertensive drugsAntihypertensive drugsThiazide diuretics and ACE inhibitor and β-blocker for 8 weeks
Primary Outcome Measures
NameTimeMethod
Systolic (SBP) and diastolic (DBP) blood pressure reductionsBefore treatment, 8 weeks during treatment
Secondary Outcome Measures
NameTimeMethod
Cardiac eventBefore treatment, 24 weeks follow-up
Death incidentBefore treatment, 24 weeks follow-up
Scores for symptoms and signsBefore treatment, 8 weeks during treatment

Trial Locations

Locations (1)

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath